7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The discovery of metabolite-phenotype associations may highlight candidate biomarkers and metabolic pathways altered in disease states. We sought to identify novel metabolites associated with obesity and one of its major complications, nonalcoholic fatty liver disease (NAFLD), using a liquid chromatography–tandem mass spectrometry method. In 997 individuals in Framingham Heart Study Generation 3 (FHS Gen 3), we identified an association between anandamide (AEA) and BMI. Further examination revealed that AEA was associated with radiographic hepatic steatosis. In a histologically defined NAFLD cohort, AEA was associated with NAFLD severity, the presence of nonalcoholic steatohepatitis, and fibrosis. These data highlight AEA as a marker linking cardiometabolic disease and NAFLD severity.

          Abstract

          The endocannabinoid anandamide is a marker in community-dwelling participants that links obesity and nonalcoholic fatty liver disease severity.

          Related collections

          Author and article information

          Contributors
          Journal
          JCI Insight
          JCI Insight
          JCI Insight
          JCI Insight
          American Society for Clinical Investigation
          2379-3708
          4 May 2017
          4 May 2017
          4 May 2017
          : 2
          : 9
          : e92989
          Affiliations
          [1 ]Center for Genomic Medicine, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
          [2 ]Division of Cardiovascular Medicine, Beth Israel Deaconess Hospital, Boston, Massachusetts, USA.
          [3 ]Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
          [4 ]Framingham Heart Study of the National Heart, Lung, and Blood Institute and Boston University School of Medicine, Framingham, Massachusetts, USA.
          [5 ]Biostatistics Department, Boston University School of Public Health, Boston, Massachusetts, USA.
          [6 ]Section of Gastroenterology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
          [7 ]Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
          [8 ]Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
          Author notes
          Address correspondence to: Robert E. Gerszten, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02115, USA. Phone: 617.632.7647; E-mail: rgerszte@ 123456bidmc.harvard.edu .
          Author information
          http://orcid.org/0000-0002-2519-8530
          http://orcid.org/0000-0001-6131-3981
          Article
          PMC5414569 PMC5414569 5414569 92989
          10.1172/jci.insight.92989
          5414569
          28469090
          8c68ec73-86ca-4dab-95c1-e51a10c32587
          Copyright © 2017, American Society for Clinical Investigation
          History
          : 23 January 2017
          : 4 April 2017
          Categories
          Research Article

          Gastroenterology,Metabolism
          Gastroenterology, Metabolism

          Comments

          Comment on this article